Immune cell combo shows promise against tough gynecologic cancers
NCT ID NCT07434284
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a new treatment that combines specially grown immune cells (cCTL) with immunotherapy for people with advanced gynecologic cancers like ovarian, cervical, or endometrial cancer. The goal is to see if the combination is safe and can shrink tumors. About 5 to 20 participants who have not responded to standard treatments will be enrolled.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED CERVICAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Obstetrics and Gynecology Hospital of Fudan University
RECRUITINGShanghai, Shanghai Municipality, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could centralized surgery boost ovarian cancer survival?
- Real-World check: can a targeted ovarian cancer drug deliver outside clinical trials?
- Could a cheaper copy of a key chemo drug work just as well?
- Acupuncture with a jolt: could needles shield nerves from chemo?
- Engineered immune cells take on Hard-to-Treat ovarian and endometrial cancers
- New cocktail aims to stall ovarian cancer